Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars

Molecular Genetics and Metabolism

Volumn 103, Issue 1, 2011, Pages 26-32

  Tsukimura, Takahiro ^a   Chiba, Yasunori ^a,b   Ohno, Kazuki ^c   Saito, Seiji ^d   Tajima, Youichi ^a,e   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c NPO for the Promotion of Research on Intellectual Property Tokyo   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Galactosidase A; Fabry disease; Imino sugar; Molecular interaction; Pharmacological chaperone

Indexed keywords

ALPHA GALACTOSIDASE; CHAPERONE; GALACTOSTATIN BISULFITE; IMINOSUGAR; MIGALASTAT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; FABRY DISEASE; MOLECULAR INTERACTION; NONHUMAN; PH; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; YEAST;

ALPHA-GALACTOSIDASE; AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; ENZYME STABILITY; IMINO SUGARS; MODELS, MOLECULAR; MUTANT PROTEINS; PROTEIN BINDING;

EID: 79955129897     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.01.013     Document Type: Article

References (40)

1. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. McGraw-Hill Inc., New York. Eighth ed. C.R. Scriver, W.A. Sly, A.L. Beaudet, D. Valle (Eds.).
2. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA 2008, 105:2812-2817.
3. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnich R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006, 79:31-40.
4. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., Anderson T., Gillespie F., Oliver K.L., Jeffries N.O., Doo E., Liang T.J., Kreps C., Gunter K., Frei K., Crutchfield K., Selden R.F., Brady R.O. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 2000, 97:365-370.
5. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345:9-16.
6. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 2009, 1:268-279.
7. Ishii S., Chang H.-H., Kawasaki K., Yasuda K., Wu H.-L., Garman S.C., Fan J.-Q. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem. J. 2007, 406:285-295.
8. Hamanaka R., Shinohara T., Yano S., Nakamura M., Yasuda A., Yokoyama S., Fan J.-Q., Kawasaki K., Watanabe M., Ishii S. Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. Biochim. Biophys. Acta 2008, 1782:408-413.
9. Yam G.H.F., Zuber C., Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J. 2005, 19:12-18.
10. Yam G.H.F., Bosshard N., Zuber C., Steinmann B., Roth J. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am. J. Physiol. Cell Physiol. 2006, 290:C1076-C1082.
11. Fan J.-Q., Ishii S., Asano N., Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 1999, 5:112-115.
12. Sugawara K., Tajima Y., Kawashima I., Tsukimura T., Saito S., Ohno K., Iwamoto K., Kobayashi T., Itoh K., Sakuraba H. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol. Genet. Metab. 2009, 96:233-238.
13. Shin S.H., Murray G.J., Kluepfel-Stahl S., Cooney A.M., Quirk J.M., Schiffmann R., Brady R.O., Kaneski C.R. Screening for pharmacological chaperones in Fabry disease. Biochem. Biophys. Res. Commun. 2007, 359:168-173.
14. Shin S.H., Kluepfel-Stahl S., Cooney A.M., Kaneski C.R., Quirk J.M., Schiffmann R., Brady R.O., Murray G.J. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet. Genomics 2008, 18:773-780.
15. Shimotori M., Maruyama H., Nakamura G., Suyama T., Sakamoto F., Itoh M., Miyabayashi S., Ohnishi T., Sakai N., Wataya-Kaneda M., Kubota M., Takahashi T., Mori T., Tamura K., Kageyama S., Shio N., Maeba T., Yahagi H., Tanaka M., Oka M., Sugiyama H., Sugawara T., Mori N., Tsukamoto H., Tamagaki K., Tanda S., Suzuki Y., Shinonaga C., Miyazaki J., Ishii S., Gejyo F. Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum. Mutat. 2008, 29:331.
16. Benjamin E.R., Flanagan J.J., Schilling A., Chang H.H., Agarwal L., Katz E., Wu X., Pine C., Wustman B., Desnick R.J., Lockhart D.J., Valenzano K.J. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J. Inherit. Metab. Dis. 2009, 32:424-440.
17. Park J.Y., Kim G.H., Kim S.S., Ko J.M., Lee J.J., Yoo H.W. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease. Exp. Mol. Med. 2009, 41:1-7.
18. Filoni C., Caciotti A., Carraresi L., Cavicchi C., Parini R., Antuzzi D., Zampetti A., Feriozzi S., Poisetti P., Garman S.C., Guerrini R., Zammarchi E., Donati M.A., Morrone A. Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim. Biophys. Acta 2010, 1802:247-252.
19. Ishii S., Chang H.-H., Yoshioka H., Shimada T., Mannen K., Higuchi Y., Taguchi A., Fan J.-Q. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J. Pharmacol. Exp. Ther. 2009, 328:723-731.
20. Khanna R., Soska R., Lun Y., Feng J., Frascella M., Young B., Brignol N., Pellegrino L., Sitaraman S.A., Desnick R.J., Benjamin E.R., Lockhart D.J., Valenzano K.J. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol. Ther. 2010, 18:23-33.
21. Lieberman R.L., D'aquino J.A., Ringe D., Petsko G.A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 2009, 48:4816-4827.
22. Dudek M.J., Ponder J.W. Accurate modeling of the intramolecular electrostatic energy of proteins. J. Comput. Chem. 1995, 16:791-816.
23. Kong M.J., Ponder J.W. Reaction field methods for off-center multipoles. J. Comput. Chem. 1997, 107:481-492.
24. Kundrot C.E., Ponder J.W., Richards F.M. Algorithms for calculating excluded volume and its derivative as a function of molecular conformation and their use in energy minimization. J. Comput. Chem. 1991, 12:402-409.
25. Pappu R.V., Hart R.W., Ponder J.W. Analysis and application of potential energy smoothing for global optimization. J. Phys. Chem. B 1998, 102:9725-9742.
26. Ren P., Ponder J.W. Polarizable atomic multipole water model for molecular mechanics simulation. J. Phys. Chem. B 2003, 107:5933-5947.
27. Garman S.C., Garboczi D.N. The molecular defect leading to Fabry disease: Structure of human α-galactosidase. J. Mol. Biol. 2004, 337:319-335.
28. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A 1976, 32:827.
29. Kabsch W. A discussion of the solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A 1978, 34:922-923.
30. Sakuraba H., Matsuzawa F., Aikawa S., Doi H., Kotani M., Lin H., Ohno K., Tanaka A., Yamada H., Uyama E. Molecular and structural studies of the GM2 gangliosidosis O variant. J. Hum. Genet. 2002, 47:176-183.
31. Matsuzawa F., Aikawa S., Doi H., Okumiya T., Sakuraba H. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Hum. Genet. 2005, 117:317-328.
32. Sugawara K., Ohno K., Saito S., Sakuraba H. Structural characterization of mutant alpha-galactosidases causing Fabry disease. J. Hum. Genet. 2008, 53:812-824.
33. Sakuraba H., Matsuzawa F., Aikawa S., Doi H., Kotani M., Nakada H., Fukushige T., Kanzaki T. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J. Hum. Genet. 2004, 49:1-8.
34. Weiner S.J., Kallman P.A., Case D.A., Singh U.C., Ghio C. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 1984, 106:765-784.
35. McDonald I.K., Thornton J.M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 1994, 238:777-793.
36. Ishii S., Kase R., Sakuraba H., Suzuki Y. Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem. Biophys. Res. Commun. 1993, 197:1585-1589.
37. Akeboshi H., Chiba Y., Kasahara Y., Takashiba M., Takaoka Y., Ohsawa M., Tajima Y., Kawashima I., Tsuji D., Itoh K., Sakuraba H., Jigami Y. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta. Appl. Environ. Microbiol. 2007, 73:4805-4812.
38. Mayes J.S., Scheerer J.B., Sifers R.N., Donaldson M.L. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin. Chim. Acta 1981, 112:247-251.
39. Sakuraba H., Chiba Y., Kotani M., Kawashima I., Ohsawa M., Tajima Y., Takaoka Y., Jigami Y., Takahashi H., Hirai Y., Shimada T., Hashimoto Y., Ishii K., Kobayashi T., Watabe K., Fukushige T., Kanzaki T. Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery. J. Hum. Genet. 2006, 51:341-352.
40. Kuroda K., Kobayashi K., Tsumura H., Komeda T., Chiba Y., Jigami Y. Production of Man5GlcNAc2-type sugar chain by the methylotrophic yeast Ogataea minuta. FEMS Yeast Res. 2006, 6:1052-1062.